Obstructive Sleep Apnea Syndrome
Conditions
Keywords
OSAS, AHI, MRA, CFD
Brief summary
In this open prospective study 40 patients who received Mandibular Replacement Appliance (MRA) Therapy as treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) will be included. The patient's sleep will be registered during 2 periods of 2 days: one while the patient does not wear the MRA and, +/- 1 week later, one while the patient wears the MRA. Furthermore, 2 low dose CT scans (one with and one without the MRA device in the mouth) will be taken. These data must allow the investigators to validate the use of functional imaging (segmentation and Computational Fluid Dynamics) as a predictor of the outcome of the MRA therapy in OSAHS patients.
Interventions
RADIATIONCT scan
low dose radiation scan without contrast without and with MRA
DEVICEAlice PDx polygraphy
Alice PDx polygraphy (Respironics)
Sponsors
University Hospital, Antwerp
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with documented OSAHS based on the following criteria: AHI \>= 5 Complaints of extreme daytime sleepiness with no other explanation and/or 2 or more of the following symptoms: * choking or gasping during sleep * recurrent awakenings from sleep * un-refreshing sleep * daytime fatigue * impaired concentration 2. Patients who received MRA as treatment for OSAHS 3. AHI \>= 5 on at least 1 of the screening nights (patient does not wear MRA device) 4. Male or female patients aged ≥ 18 years 5. Patients with a co-operative attitude 6. Written informed consent obtained
Exclusion criteria
1. Pregnant or lactating females or females at risk of pregnancy 2. Patients with an uncontrolled disease or any condition that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study. 3. Cancer or any other chronic disease with poor prognosis and/or affecting patient status 4. History of alcohol or drug abuse in the last 2 years 5. Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study 6. Patients who participate in another clinical study whose investigational plan is judged to interfere or affect any of the measures of this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| changes in mean AHI between visit 1 and visit 2 | visit 1 (AHI of 2 nights without MRA) / visit 2 (AHI of 2 nights with MRA) (visit 2 happens +/- 1 week after visit 1) | evaluate the predictive value of upper airway segmentation and CFD analysis on responsiveness to MRA therapy in OSAHS patients |
| changes in UA resistance | 1 CT scan without MRA (UA resistance without MRA) / 1 CT scan with MRA (UA resistance with MRA) | evaluate the predictive value of upper airway segmentation and CFD analysis on responsiveness to MRA therapy in OSAHS patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| changes in mean ESS between visit 1 and visit 2 | visit 1 (ESS of 2 nights without MRA) / visit 2 (ESS of 2 nights with MRA) (visit 2 happens +/- 1 week after visit 1) | to assess the effect of the MRA therapy on daytime sleepiness with the Epworth Sleepiness Scale (ESS). |
Countries
Belgium
Contacts
Primary ContactWilfried De Backer, MD
Backup ContactAnnemie Hufkens, MSc
Outcome results
None listed